UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q/A

 

Amendment No. 1

 

 

(Mark One)

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2013

 

OR

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

 

Commission file number: 001-36167

 

Karyopharm Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

 

(508) 975-4820

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes o No x

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No x

 

As of December 16, 2013, there were 29,749,593 shares of Common Stock, $0.0001 par value per share, outstanding.

 

 

 

Explanatory Note

 

The purpose of this Amendment No. 1 on Form 10-Q/A to Karyopharm Therapeutic Inc.’s quarterly report on Form 10-Q for the quarter ended September 30, 2013, filed with the Securities and Exchange Commission on December 20, 2013 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.

 

No other changes have been made to the Form 10-Q. This Amendment No. 1 speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10-Q.

 

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

2

 

Item 6.  Exhibits.

 

The exhibits filed as part of this Quarterly Report on Form 10-Q/A are set forth on the Exhibit Index hereto, which Exhibit Index is incorporated herein by reference.

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	KARYOPHARM THERAPEUTICS INC.
Date: December 23, 2013	By:	/s/ PAUL BRANNELLY
		Paul Brannelly
		Senior Vice President, Finance & Administration
		(Principal financial and accounting officer)

 

4

 

EXHIBIT INDEX

 

Exhibit Number

Description of Exhibit

Incorporated by Reference

Filed Herewith

Form

File Number

Date of Filing

Exhibit Number

3.1

Restated Certificate of Incorporation

8-K

3.2

Amended and Restated By-Laws

8-K

10.1

2013 Stock Incentive Plan

S-1/A

333-191584

10/28/13

10.3

10.2

Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan

S-1/A

333-191584

10/28/13

10.4

10.3

Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan

S-1/A

333-191584

10/28/13

10.5

10.4

2013 Employee Stock Purchase Plan

S-1/A

333-191584

10/28/13

10.6

31.1

Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

10-Q

001-36167

12/20/13

31.1

31.2

Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

10-Q

001-36167

12/20/13

31.2

32.1

Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10-Q

001-36167

12/20/13

32.1

32.2

Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10-Q

001-36167

12/20/13

32.2

101.INS

XBRL Instance Document*

X

101.SCH

XBRL Taxonomy Extension Schema Document*

X

101.CAL

XBRL Taxonomy Calculation Linkbase Document*

X

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document*

X

101.LAB

XBRL Taxonomy Label Linkbase Document*

X

 

*                 Submitted electronically herewith

 

5